Combination of ibudilast and riluzole and methods of using same

Abstract

The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.

1 .- 22 . (canceled) 
     
     
         23 . A composition for oral administration, comprising:
 (a) ibudilast or a pharmaceutically acceptable salt thereof,   (b) riluzole or a pharmaceutically acceptable salt thereof, and   (c) optionally, a pharmaceutically acceptable excipient or carrier.   
     
     
         24 . The composition of claim  0 , comprising ibudilast or a pharmaceutically acceptable salt thereof in an amount from about 100 mg to about 4,000 mg, divided into one, two, or three portions. 
     
     
         25 . The composition of claim  0 , comprising riluzole or pharmaceutically acceptable salt thereof in an amount from about 50 mg to about 4,000 mg, divided into one, two, or three portions. 
     
     
         26 . The composition of claim  0 , comprising from about 100 mg to about 4,000 mg of ibudilast or a pharmaceutically acceptable salt thereof and from about 50 mg to about 4,000 mg of riluzole or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The composition of claim  0 , wherein the ibudilast and the riluzole are in a single tablet or a single capsule dosage form. 
     
     
         28 . The composition of claim  0 , wherein the ibudilast and the riluzole are in a liquid dosage form. 
     
     
         29 .- 40 . (canceled) 
     
     
         41 . A method of reducing a volume of an infarct (an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus) in a patient suffering from an ischemia, comprising administering to a patient in need thereof:
 (d) a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, and   (e) a therapeutically effective amount of riluzole or a pharmaceutically acceptable salt thereof,   in which a volume of an infarct in the treated patient is reduced compared to a volume of an infarct in a control patient.   
     
     
         42 . The method of claim  0 , in which the ibudilast or a pharmaceutically acceptable salt thereof and the riluzole or a pharmaceutically acceptable salt thereof are administered orally. 
     
     
         43 . The method of claim  0 , in which the ibudilast or a pharmaceutically acceptable salt thereof and riluzole or a pharmaceutically acceptable salt thereof are administered in a tablet or a capsule dosage form. 
     
     
         44 . The method of claim  0 , in which the ibudilast or a pharmaceutically acceptable salt thereof and riluzole or a pharmaceutically acceptable salt thereof are administered in a liquid dosage form. 
     
     
         45 . The composition of claim  0 , wherein the ibudilast or a pharmaceutically acceptable salt thereof is administered in an amount from about 100 mg to about 4,000 mg/day, divided into one, two, or three portions. 
     
     
         46 . The method of claim  0 , in which the riluzole or a pharmaceutically acceptable salt thereof is administered in an amount from about 1 mg/kg/day to about 1000 mg/kg/day of the patient, divided into one, two, or three portions. 
     
     
         47 . The method of claim  0 , wherein the ibudilast and the riluzole are administered simultaneously in a single dosage form. 
     
     
         48 . The method of claim  0 , wherein the ibudilast and the riluzole are administered in separate dosage forms. 
     
     
         49 .- 62 . (canceled)